IVIG and COVID19

Intravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200501047259N1

Enrollment

Registered

2020-05-17

Start date

2020-05-09

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19. COVID19

Interventions

Immune Globulin intravenous (human) flebogamma 5% DIF GRIFOLS will be used, each vial has 5 gram IVIG and patient will receive 4 vial every day for 3 days.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: stablished COVID 19 in PCR test age more than 18 no response to at least one antiviral and chloroquine drugs more than 30% involvement in chest computed tomography

Exclusion criteria

Exclusion criteria: pregnant women coagulopathies previous hypersensitivity to IVIG left ventricular ejection fraction less than 35% previous lung fibrosis or lung surgery LUNG SARCOIDOSIS OR TUBERCULOSIS

Design outcomes

Primary

Measure	Time frame
Increasing of patient's O2 saturation above 90%, improvement of lung involvement in lung CT scan. Timepoint: before discharge. Method of measurement: percentile.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNaser Gharebaghi

Oroumia University of Medical Sciences

hajizadh.reza@gmail.com+98 44 3344 4593

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 25, 2026